Doug Podolsky

This article provides an overview of the key risks that can be associated with the use of secondary reference standards (RS) and illustrates scientific challenges associated with transitioning from pharmacopeial RS to secondary RS.

Survey results indicate that the current regulatory approval pathway for excipients creates a challenge for the use of novel excipients.